BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope

Genetic therapies compete in the same indications, as degraders come of age

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

A scientific consensus-building process on neuronal mucopolysaccharidoses biomarkers could set powerful precedent

More than half of clinical AAV programs target neurology and ophthalmic conditions

Why crossovers flooded series D for gene therapy play RegenxBio